XRTX
Xyratex Ltd.
NASDAQ · Healthcare · Biotechnology · CA
$1.01
+0.50%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -28.3%
- EBIT
- -16.3%
- EPS
- -45.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +17.3%
- EBIT
- +17.0%
- Net income
- +15.8%
- EPS
- +48.9%
- Free cash flow
- +24.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026